

Filed on behalf of: Janssen Biotech, Inc.

Entered: October 5, 2026

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ACCORD BIOPHARMA, INC., INTAS PHARMACEUTICALS LTD., AND
BIO-THERA SOLUTIONS, LTD.,
Petitioner,

v.

JANSSEN BIOTECH, INC.,
Patent Owner.

IPR2026-00259
Patent No. 12,291,566

PATENT OWNER'S UPDATED EXHIBIT LIST

Pursuant to 37 C.F.R. § 42.63(e), Patent Owner respectfully submits the following updated Exhibit List:

Exhibit	Description
2001	Prosecution History for U.S. Patent No. 11,014,982 B2 (“’982 Patent PH”) (EXCERPT)
2002	Prosecution History for U.S. Patent No. 12,291,566 B2 (“’566 Patent PH”) (EXCERPT)
2003	U.S. Patent Application Publication No. US 2021/0238271 A1 (“’271 Publication”)
2004	RESERVED
2005	Proposed Protective Order
2006	Proposed Protective Order Redline
2007	Press Release, Johnson & Johnson, Simponi® Aria™ (Golimumab) for Infusion Receives FDA Approval for Treatment of Moderately to Severely Active Rheumatoid Arthritis (July 18, 2013), https://www.jnj.com/media-center/press-releases/simponi-aria-golimumab-for-infusion-receives-fda-approval-for-treatment-of-moderately-to-severely-active-rheumatoid-arthritis (“J&J 7/18/2013 PressRelease”)
2008– 2011	RESERVED
2012	Press Release, Johnson & Johnson, Johnson & Johnson to Break Ground on New State-of-The-Art Biologics Facility in North Carolina to Deliver Market-Leading Portfolio of Transformational Therapies (Mar. 21, 2025), https://www.jnj.com/media-center/press-releases/johnson-johnson-to-break-ground-on-new-state-of-the-art-biologics-facility-in-north-carolina-to-deliver-market-leading-portfolio-of-transformational-therapies (“J&J 3/21/2025 Press Release”)

Exhibit	Description
2013	Press Release, Johnson & Johnson, Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments (Jan. 8, 2026), https://www.jnj.com/media-center/press-releases/johnson-johnson-reaches-agreement-with-u-s-government-to-improve-access-to-medicines-and-lower-costs-for-millions-of-americans-delivers-on-u-s-manufacturing-and-innovation-investments (“J&J 1/8/2026 Press Release”)
2014	FDA, SIMPONI ARIA [®] (Golimumab) Prescribing Information (revised Apr. 2025), https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/SIMPONI+ARIA-pi.pdf (“SIMPONI ARIA [®] FDA Label”)
2015	Bio-Thera Solutions, Ltd., 2019 Annual Report (Chinese)
2016	English Translation and Certificate of Translation of an excerpt of Exhibit 2015 (Bio-Thera Solutions, Ltd., 2019 Annual Report) (“Bio-Thera 2019 Ann. Rep.”)
2017– 2018	RESERVED
2019	Bio-Thera Solutions, Ltd., 2021 Annual Report (Chinese)
2020	English Translation and Certificate of Translation of an excerpt of Exhibit 2019 (Bio-Thera Solutions, Ltd., 2021 Annual Report) (“Bio-Thera 2021 Ann. Rep.”)
2021	Bio-Thera Solutions, Ltd., 2024 Annual Report (Chinese)
2022	English Translation and Certificate of Translation of an excerpt of Exhibit 2021 (Bio-Thera Solutions, Ltd., 2024 Annual Report) (“Bio-Thera 2024 Ann. Rep.”)
2023	Bio-Thera Solutions, Ltd., 2025 Semi-Annual Report (Chinese)

Exhibit	Description
2024	English Translation and Certificate of Translation of an excerpt of Exhibit 2023 (Bio-Thera Solutions, Ltd., 2025 Semi-Annual Report) (“Bio-Thera 2025 Semi-Ann. Rep.”)
2025	RESERVED
2026	Factset Research Systems Inc., FactSet Entity Data Management: Accord BioPharma, Inc. (0TBGSZ-E) - Subsidiary (Apr. 2, 2026) (“Accord Entity Data”)
2027	PitchBook Data, Inc., Intas Pharmaceuticals Private Company Profile (Mar. 16, 2026) (“Intas Pharms. Profile”)
2028	Company News, Bio-Thera Solutions, Ltd., Bio-Thera Solutions Announces Further Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (Golimumab), Through Exclusive Commercialization and License Agreement in India (Mar. 23, 2026), https://www.bio-thera.com/col_62/1390.html (“Bio-Thera 3/23/2026 News”)
2029– 2030	RESERVED
2031	<i>The Chinese Government’s Evolving Control of The Nonstate Sector: Rep. to Cong. of the U.S.-China Econ. & Sec. Rev. Comm’n</i> , 117th Cong. 214–239 (Nov. 2021), https://www.uscc.gov/sites/default/files/2021-11/Chapter_2_Section_3--Chinese_Governments_Evolving_Control_of_the_Nonstate_Sector.pdf (“2021 Cong. Rep.”)
2032	RESERVED
2033	Memorandum from the Acting Under Sec’y of Com. for Intell. Prop. & Acting Dir. of the USPTO to Members of the P.T.A.B. (July 31, 2025), https://www.uspto.gov/sites/default/files/documents/aapa_memo_final__signed.pdf (“7/31/2025 Acting Dir. Mem.”)

Exhibit	Description
2034	Memorandum from the Under Sec'y of Com. for Intell. Prop. & Dir. of the USPTO to All P.T.A.B. Users (Mar. 11, 2026), https://www.uspto.gov/sites/default/files/documents/Additional_Discretionary_Institution_Considerations_US_Manufacturing_and_Small_Business_Use_of_AIA_Proceedings.pdf (“3/11/2026 Dir. Mem.”)
2035	RESERVED
2036	Tomas Gabriel Bas, <i>Innovative Formulation Strategies for Biosimilars: Trends Focused on Buffer-Free Systems, Safety, Regulatory Alignment, and Intellectual Property Challenges</i> , 18 PHARMS. 908 (2025) (“Bas (2025)”)
2037	Max Beauroyre, <i>Clinical-Trial Costing 101: Building a Phase-by-Phase Budget Your Board Will Trust</i> , ABACUM (June 25, 2025), https://www.abacum.ai/blog/clinical-trial-costing (“Beauroyre (2025)”)
2038– 2039	RESERVED
2040	Hirotaka Nonaka, FTO (FREEDOM TO OPERATE) IN THE PHARMACEUTICAL INDUSTRY 16–33 (MIPLC Studies Vol. 34, 1st ed. 2018), https://www.jstor.org/content/oa_chapter_monograph/j.ctv941tn6.5?seq=1 (“Nonaka (2018)”) (EXCERPT)
2041– 2042	RESERVED
2043	Qichacha (QCC), Bio-Thera Solutions, Ltd. Enterprise Credit Report (Chinese)
2044	English Translation and Certificate of Translation of an excerpt of Exhibit 2043 (Qichacha (QCC) Report, Bio-Thera Solutions, Ltd. Enterprise Credit Report Professional Edition, Report No. 1775619203666287 Report Verification No.: sq0MJfAi (Apr. 8, 2026, 11:33:51 a.m.)) (“Bio-Thera Credit Rep.”)

Exhibit	Description
2045	Qichacha (QCC), Bio-Thera Solutions, Ltd. Partnership Chart (Chinese)
2046	English Translation and Certificate of Translation of an excerpt of Exhibit 2045 (Qichacha (QCC) Report, Bio-Thera Solutions Ltd. w-Guangzhou Zhongke Yuechuang No. 3 Venture Capital Partnership (Apr. 8, 2026)) (“Bio-Thera Partnership Rep.”)
2047	Press Release, N.C. Off. of Governor Josh Stein, Governor Stein Announces Johnson & Johnson Will Build Second Major Facility in Wilson County (Jan. 9, 2026), https://governor.nc.gov/news/press-releases/2026/01/09/governor-stein-announces-johnson-johnson-will-build-second-major-facility-wilson-county (“N.C. Gov. Press Release”)
2048	David Shealy et al., Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α , 2 LANDES BIOSCIENCE 428 (2010), https://www.tandfonline.com/doi/full/10.4161/mabs.12304 (“Shealy (2010)”)
2049	RESERVED
2050	Press Release, Accord BioPharma, FDA Approves IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi), First Biosimilars to Simponi® (golimumab) and Simponi Aria® (golimumab); Accord BioPharma to Lead U.S. Commercialization (5/18/2026, 12:05 ET), https://www.accordbiopharma.com/news/fda-approves-immgol-is-golimumab-sldi-and-immgol-is-intri-golimumab-sldi-first-biosimilars-to-simponi-golimumab-and-simponi-aria-golimumab-accord-biopharma-to-lead/ (“Accord 5/18/2026 Press Release”)
2051	Memorandum from the Under Sec’y of Com. for Intell. Prop. & Dir. of the USPTO to All P.T.A.B. Judges (Oct. 28, 2025), https://www.uspto.gov/sites/default/files/documents/Precedential_designation_of_Corning_Optical_Communications_RF_LLC_v._PPC_Broadband_Inc_Memo_-_Dated_10_28_25.pdf (“10/28/2025 Dir. Mem.”)

Exhibit	Description
2052	Eur. Meds. Agency, Sci. Meds. Health, Comm. for Med. Prods. for Hum. Use (Day 120 Assessment Report, EMA/416184/2014), Withdrawal Assessment Report: Simponi (golimumab), EMEA/H/C/000992/X/0047 (Janssen Biologics B.V., Applicant) (Oct. 24, 2013)
2053	Ctr. for Drug Evaluation & Rsch., Clinical Pharm. & Biopharmaceutics Rev., Simponi (Golimumab), BLA Appl. No. 125289 (submitted June 24, 2008) (EXCERPTS)
2054	Declaration of Dr. Nigil Haroon, M.D., Ph.D., M.B.A. in Support of Patent Owner's Preliminary Response ("Haroon")
2055	<i>Curriculum Vitae</i> of Dr. Nigil Haroon
2056	Press Release, Johnson & Johnson, <i>Janssen Receives Two U.S. FDA Approvals for Simponi Aria® (Golimumab) for the Treatment of Adults With Active Psoriatic Arthritis or Active Ankylosing Spondylitis</i> (Oct. 20, 2017), https://www.jnj.com/media-center/press-releases/janssen-receives-two-us-fda-approvals-for-simponi-aria-golimumab-for-the-treatment-of-adults-with-active-psoriatic-arthritis-or-active-ankylosing-spondylitis
2057	NIH, Nat'l Lib. of Med., Nat'l Ctr. for Biotechnology Info., ClinicalTrials.gov: Search operation, https://clinicaltrials.gov/ (last visited May 3, 2026)
2058	NIH, Nat'l Lib. of Med., Nat'l Ctr. for Biotechnology Info., ClinicalTrials.gov, <i>An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis</i> (Janssen Rsch. & Dev., LLC, ClinicalTrials.gov ID NCT00488774) (updated June 14, 2013), https://clinicaltrials.gov/study/NCT00488774
2059	NIH, Nat'l Lib. of Med., Nat'l Ctr. for Biotechnology Info., ClinicalTrials.gov, <i>Study of Adalimumab in Patients With Axial Spondyloarthritis</i> (AbbVie, ClinicalTrials.gov ID NCT00939003) (updated Sept. 9, 2014), https://clinicaltrials.gov/study/NCT00939003

Exhibit	Description
2060	RESERVED
2061	RESERVED
2062	NIH, Nat'l Lib. of Med., Nat'l Ctr. for Biotechnology Info., ClinicalTrials.gov, <i>A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis (COAST-V)</i> (Eli Lilly & Co., ClinicalTrials.gov ID NCT02696785) (updated Nov. 19, 2019), https://clinicaltrials.gov/study/NCT02696785
2063	NIH, Nat'l Lib. of Med., Nat'l Ctr. for Biotechnology Info., ClinicalTrials.gov, <i>A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis (COAST-W)</i> (Eli Lilly & Co., ClinicalTrials.gov ID NCT02696798) (updated June 17, 2020), https://clinicaltrials.gov/study/NCT02696798
2064	Internet Archive Wayback Machine, Calendar of https://clinicaltrials.gov/study/NCT02186873 , https://web.archive.org/web/20230915000000*/https://clinicaltrials.gov/study/NCT02186873 (last visited May 21, 2026)
2065	Internet Archive Wayback Machine, Search of ClinicalTrials.gov studies, https://web.archive.org/web/20151118232332/https://clinicaltrials.gov/ (last visited May 3, 2026)
2066	FDA, Cosentyx Prescribing Information (revised Jan. 2016) ("Cosentyx")
2067	FDA, Kevzara Prescribing Information (revised Apr. 2018) ("Kevzara")
2068	FDA, Remicade Prescribing Information (revised Oct. 2015) ("Remicade")
2069	Jennifer J. Anderson et al, <i>Ankylosing Spondylitis Assessment Group Preliminary Definition of Short-Term Improvement in Ankylosing Spondylitis</i> , 44 ARTHRITIS RHEUMATISM 1876 (2001)

Exhibit	Description
2070	RESERVED
2071	Anthony D. Bai et al, <i>Intention-To-Treat Analysis May Be More Conservative Than Per Protocol Analysis in Antibiotic Non-Inferiority Trials: A Systematic Review</i> , 21 BMC MED. RSCH. METHODOLOGY 1–10 (2021)
2072	X. Baraliakos et al, <i>Radiographic Progression in Patients With Ankylosing Spondylitis After 4 Yrs of Treatment With the Anti-TNF-α Antibody Infliximab</i> , 46 RHEUMATOLOGY 1450 (2007)
2073	L.C. Doward et al, <i>Development of the ASQoL: A Quality of Life Instrument Specific to Ankylosing Spondylitis</i> , 62 ANNALS RHEUMATIC DISEASES 20 (2003)
2074	Mazen Elyan & Muhammad Asim Khan, <i>Diagnosing Ankylosing Spondylitis</i> , 33 J. RHEUMATOLOGY 12 (2006)
2075	Mathurin Flamant et al, <i>Golimumab for the Treatment of Ulcerative Colitis</i> , 17 EXPERT OP. BIOLOGICAL THERAPY 879 (2017)
2076	Mohammad Ghasemi-rad et al, <i>Ankylosing Spondylitis: A State of the Art Factual Backbone</i> , 7 WORLD J. RADIOLOGY 236 (2015)
2077	H. Haibel et al, <i>Six Months Open Label Trial of Leflunomide in Active Ankylosing Spondylitis</i> , 64 ANNALS RHEUMATIC DISEASES 124 (2005)
2078	H. Haibel et al, <i>Open Label Trial of Anakinra in Active Ankylosing Spondylitis Over 24 Weeks</i> , 64 ANNALS RHEUMATIC DISEASES 296 (2005)
2079	H. Haibel et al, <i>No Efficacy of Subcutaneous Methotrexate in Active Ankylosing Spondylitis: A 16-Week Open-Label Trial</i> , 66 ANNALS RHEUMATIC DISEASES 419 (2007)
2080	CHARLES A. JANEWAY, JR., ET AL, IMMUNOBIOLOGY-THE IMMUNE SYSTEM IN HEALTH & DISEASE ch. 3-6 (5th ed 2001), (EXCERPT), https://www.ncbi.nlm.nih.gov/books/NBK27160/

Exhibit	Description
2081	Arthur Kavanaugh et al, <i>Treatment of Psoriatic Arthritis in a Phase 3 Randomised, Placebo-Controlled Trial with Apremilast, An Oral Phosphodiesterase 4 Inhibitor</i> , 73 ANNALS RHEUMATIC DISEASES 1020 (2014)
2082	RESERVED
2083	R.J. Lories & D.L.P. Baeten, <i>Differences in Pathophysiology Between Rheumatoid Arthritis and Ankylosing Spondylitis</i> , 27 CLINICAL EXPERIMENTAL RHEUMATOLOGY S10 (2009)
2084	Peter Machado et al, <i>Ankylosing Spondylitis Disease Activity Score (ASDAS): Defining Cut-Off Values for Disease Activity States and Improvement Scores</i> , 70 ANNALS RHEUMATIC DISEASES 47 (2011)
2085	W.P. Maksymowych and M.A. Brown, <i>Genetics of Ankylosing Spondylitis and Rheumatoid Arthritis: Where Are We At Currently, and How Do They Compare?</i> , 27 CLINICAL EXPERIMENTAL RHEUMATOLOGY S20 (2009)
2086	Dennis McGonagle et al, <i>Classification of Inflammatory Arthritis by Enthesitis</i> , 352 LANCET 1137 (1998)
2087	D.R. Mould & R.N. Upton, <i>Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling Methods</i> , 2 CPT: PHARMACOMETRICS SYS. PHARMACOLOGY 1–14 (2013)
2088	Philip Ian Murray & Saaeha Rauz, <i>The Eye and Inflammatory Rheumatic Diseases: The Eye and Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis</i> , 30 BEST PRAC. RSCH. CLINICAL RHEUMATOLOGY 802 (2016)
2089	Dušan Mustur et al, <i>Assessment of Functional Disability and Quality of Life in Patients with Ankylosing Spondylitis</i> , 137 SERBIAN ARCHIVES MED. 524 (2009)

Exhibit	Description
2090	Makoto Naganuma et al, <i>Recent Trends and Future Directions for the Medical Treatment of Ulcerative Colitis</i> , 9 CLINICAL J. GASTROENTEROLOGY 329 (2016)
2091	Karel Pavelka et al, <i>A Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate</i> , 42 J. RHEUMATOLOGY 912 (2015)
2092	M. Rudwaleit et al, <i>MRI in Predicting a Major Clinical Response to Anti-Tumour Necrosis Factor Treatment in Ankylosing Spondylitis</i> , 67 ANNALS RHEUMATIC DISEASES 1276 (2008)
2093	Rita Rugienė et al, <i>The Quality of Life and Functional Ability in Patients with Ankylosing Spondylitis</i> , 15 ACTA MEDICA LITUANICA 99 (2008)
2094	P. Rutgeerts et al, <i>Randomised Clinical Trial: A Placebo-Controlled Study of Intravenous Golimumab Induction Therapy for Ulcerative Colitis</i> , 42 ALIMENTARY PHARMACOLOGY THERAPEUTICS 504 (2015) (“Rutgeerts 2015”)
2095	P. Rutgeerts et al, <i>Supplemental Appendix</i> (2015) (“Rutgeerts App’x”)
2096	Georg Schett et al, <i>Structural Damage in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis: Traditional Views, Novel Insights Gained From TNF Blockade, and Concepts for the Future</i> , 13 ARTHRITIS RSCH. THERAPY S4 (2011)
2097	RESERVED
2098	Joachim Sieper et al, <i>Assessment of Short-Term Symptomatic Efficacy of Tocilizumab in Ankylosing Spondylitis: Results of Randomised, Placebo-Controlled Trials</i> , 73 ANNALS RHEUMATIC DISEASES 95 (2014)

Exhibit	Description
2099	Joachim Sieper et al, <i>Sarilumab for the Treatment of Ankylosing Spondylitis: Results of a Phase II, Randomised, Double-Blind, Placebo-Controlled Study (ALIGN)</i> , 74 ANNALS RHEUMATIC DISEASES 1051 (2015)
2100	Joachim Sieper et al, <i>Secukinumab Efficacy in Anti-TNF-Naive and Anti-TNF-Experienced Subjects With Active Ankylosing Spondylitis: Results from the MEASURE 2 Study</i> , 76 ANNALS RHEUMATIC DISEASES 571 (2017)
2101	I.-H. Song et al, <i>Different Response to Rituximab in Tumor Necrosis Factor Blocker–Naive Patients With Active Ankylosing Spondylitis and in Patients in Whom Tumor Necrosis Factor Blockers Have Failed, A Twenty-Four–Week Clinical Trial</i> , 62 ARTHRITIS RHEUMATISM 1290 (2010)
2102	I-H Song et al, <i>Treatment of Active Ankylosing Spondylitis With Abatacept: An Open-Label, 24-Week Pilot Study</i> , 70 ANNALS RHEUMATIC DISEASES 1108 (2011)
2103	Calen A. Steiner et al, <i>Anti-TNF Biologic Therapies Other Than Infliximab in PEDIATRIC INFLAMMATORY BOWEL DISEASE</i> 401 (P. Mamula et al eds., 2017)
2104	RESERVED
2105	Carlos Taxonera et al, <i>Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis</i> , 23 INFLAMMATORY BOWEL DISEASES 1394 (2017)
2106	Bella Ungar & Uri Kopylov, <i>Advances in the Development of New Biologics in Inflammatory Bowel Disease</i> , 29 ANNALS GASTROENTEROLOGY 243 (2016)
2107	R.N. Upton & D.R. Mould, <i>Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development: Part 3—Introduction to Pharmacodynamic Modeling Methods</i> , 3 CPT: PHARMACOMETRICS SYS. PHARMACOLOGY 1–16 (2014)

Exhibit	Description
2108	RESERVED
2109	D. van der Heijde et al, <i>Proposal of a Linear Definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and Comparison With the 2-Step and 10-Step Definitions</i> , 67 ANNALS RHEUMATIC DISEASES 489 (2008)
2110	Désirée van der Heijde et al, <i>ASDAS, a Highly Discriminatory ASAS-Endorsed Disease Activity Score in Patients With Ankylosing Spondylitis</i> , 68 ANNALS RHEUMATIC DISEASES 1811 (2009)
2111	Désirée van der Heijde et al, <i>Tofacitinib in Patients With Ankylosing Spondylitis: A Phase II, 16-Week, Randomised, Placebo-Controlled, Dose-Ranging Study</i> , 76 ANNALS RHEUMATIC DISEASES 1340 (2017)
2112	Désirée van der Heijde et al, <i>Supplementary Information: Tofacitinib in Patients With Ankylosing Spondylitis: A Phase II, 16-Week, Randomised, Placebo-Controlled, Dose-Ranging Study</i> (Ex. 2111) (2017)
2113	Karin A. van Schie et al, <i>Therapeutic TNF Inhibitors Can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange</i> , 6 NATURE SCI. REPS. 1–10 (2016)
2114	Ronald F. van Vollenhoven, <i>Sex Differences in Rheumatoid Arthritis: More Than Meets the Eye...</i> , 7 BMC MED. 1–4 (2009)
2115	RESERVED
2116	J.E. WARE & M. KOSINSKI, SF-36 PHYSICAL & MENTAL HEALTH SUMMARY SCALES: A MANUAL FOR USERS OF VERSION 1 (2d ed. 1994) (EXCERPTS)
2117	Michael E. Weinblatt, <i>Methotrexate in Rheumatoid Arthritis: A Quarter Century of Development</i> , 124 TRANSACTIONS AM. CLINICAL CLIMATOLOGICAL ASS'N 16 (2013)

Exhibit	Description
2118	John Brockbank & Dafna Gladman, <i>Diagnosis and Management of Psoriatic Arthritis</i> , 62 DRUGS 2447 (2002)
2119	Paul A.C. Lord et al., <i>Predictors of Response to Anti-TNF Therapy in Ankylosing Spondylitis: Results from the British Society for Rheumatology Biologics Register</i> , 49 RHEUMATOLOGY 563 (2010)
2120	Philip J. Mease, <i>Is There a Role for Rituximab in the Treatment of Spondyloarthritis and Psoriatic Arthritis?</i> , 39 J. RHEUMATOLOGY 2235 (2012)
2121	Masatsugo Ono et al, <i>Structural Basis for Tumor Necrosis Factor Blockade with the Therapeutic Antibody Golimumab</i> , 27 PROTEIN SCIENCE 1038 (2018)
2122	Eric M. Ruderman, <i>The Role of Concomitant Methotrexate in Biologic Therapy for Rheumatoid Arthritis</i> , 71 BULL. HOSP. JOINT DISEASES S29 (2013)
2123	Lars Fugger & Arne Svejgaard, <i>Association of MHC and Rheumatoid Arthritis HLA-DR4 and Rheumatoid Arthritis: Studies in Mice and Men</i> , 2 ARTHRITIS RSCH. 208 (2000)
2124	Declaration of Roger J. Chin Pursuant to 37 C.F.R. § 42.10(c)(2)
2125	Declaration of Kevin N. Zhang in Support of Patent Owner's Unopposed Motion for <i>Pro Hac Vice</i> Admission Under 37 C.F.R. § 42.10(c)(1)
2126	Corrected Declaration of Kevin N. Zhang in Support of Patent Owner's Unopposed Motion for <i>Pro Hac Vice</i> Admission Under 37 C.F.R. § 42.10(c)(1)
2127– 2499	RESERVED
2500	Declaration of Ann Donlon (“Donlon Decl.”) (HC-AEO MATERIAL AND REDACTED VERSIONS)

Exhibit	Description
2501	Declaration of Luke Brennan ("Brennan Decl.") (HC-AEO MATERIAL AND REDACTED VERSIONS)
2502	Declaration of Thao Marzullo ("Marzullo Decl.") (HC-AEO MATERIAL AND REDACTED VERSIONS)

Respectfully submitted,

Dated: October 5, 2026

By: / Raghav Bajaj /

Raghav Bajaj (Reg. No. 66,630)
raghav.bajaj@lw.com
Latham & Watkins LLP
300 Colorado St., Suite 2400
Austin, TX 78701
Telephone: 737.910.7370
Fax: 737.910.7301

*Counsel for Patent Owner
Janssen Biotech, Inc.*

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 5th day of October, 2026, a true and correct copy of the foregoing **Patent Owner's Updated Exhibit List and Exhibit 2126** were served by electronic mail on Petitioner's lead and backup counsel at the following email addresses:

Lora M. Green (Reg. No. 43,541)
Robert Cerwinski (to be admitted *pro hac vice*)
Keith A. Zullo (Reg. No. 37,975)
Michael Cottler (Reg. No. 79,455)
Michael W. Johnson (Reg. No. 63,731)
Heather M. Schneider (Reg. No. 56,484)
Yahn-Lin (Franklin) Chu (Reg. No. 75,946)
lgreen@geminilaw.com
rcerwinski@geminilaw.com
kzullo@geminilaw.com
mcottler@geminilaw.com
mjohnson@geminilaw.com
hschneider@geminilaw.com
fchu@geminilaw.com
GEMINI LAW LLP
32 West 39th Street, 15th Floor
New York, NY, 10018
Tel.: 301-461-9580

By: / Raghav Bajaj /

Raghav Bajaj (Reg. No. 66,630)
raghav.bajaj@lw.com
Latham & Watkins LLP
300 Colorado St., Suite 2400
Austin, TX 78701
Telephone: 737.910.7370
Fax: 737.910.7301

*Counsel for Patent Owner
Janssen Biotech, Inc.*